Novel single‐entry point injection technique for masseter hypertrophy treatment using botulinum neurotoxin based on patient‐reported comfort

Introduction Botulinum neurotoxin (BoNT) injections are widely used for the treatment of masseter muscle hypertrophy in Southeast Asia. However, there remains a lack of consensus regarding the optimal injection technique. This study aimed to compare the efficacy and patient discomfort associated wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cosmetic dermatology 2024-11, Vol.23 (11), p.3539-3543
Hauptverfasser: Wan, Jovian, Kim, Jong‐Seo, Park, Youngjin, Park, Soo Yeon, Koppert, Erik, Kim, Hee‐Jin, Yi, Kyu‐Ho
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Botulinum neurotoxin (BoNT) injections are widely used for the treatment of masseter muscle hypertrophy in Southeast Asia. However, there remains a lack of consensus regarding the optimal injection technique. This study aimed to compare the efficacy and patient discomfort associated with single‐entry point injections versus multiple three‐point injections for masseter muscle hypertrophy treatment with BoNT. Materials and Methods Sixteen participants, comprising both male and female Korean adults aged 22–63, were enrolled in the study. On the left side of the face, single‐entry point injections were administered, followed by multidirectional injections, while on the right side, three‐point injections were given. Pain intensity during the procedure was assessed using visual analogue scale scores. Result Our results revealed that participants experienced lower levels of pain with single‐entry point injections compared to three‐point injections (average visual analogue scores of 3.31 and 5.19, respectively). Conclusion These findings highlight the potential benefits of single‐entry point injections in reducing patient discomfort during masseter muscle hypertrophy treatment with BoNT. We advocate for further research to validate these findings and encourage practitioners to consider single‐entry point injections as a viable option for enhancing treatment outcomes in their clinical practice.
ISSN:1473-2130
1473-2165
1473-2165
DOI:10.1111/jocd.16461